A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776
This study is recruiting at 7 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in combination with enzalutamide, in patients with advanced solid tumors and lymphomas.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Advanced Solid Tumor
- Diffuse Large B Cell Lymphoma
- Lymphoma, T-Cell
- Mesothelioma, Malignant
- Prostatic Neoplasms, Castration-Resistant
- Endometrial Cancer
- Ovarian Clear Cell Carcinoma
- Metastatic Castration-resistant Prostate Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Novartis Pharmaceuticals
- Last updated on ClinicalTrials.gov
- August 19, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Georgia · 1
- Winship Cancer Institute of Emory University · Atlanta, GA
Illinois · 1
- University of Chicago Medical Center · Chicago, IL
Massachusetts · 1
- Massachusetts General Hospital · Boston, MA
Pennsylvania · 1
- Abramson Cancer Center of the University of Pennsylvania · Philadelphia, PA
Virginia · 1
- University of Virginia Health System · Charlottesville, VA
Washington · 2
- Fred Hutchinson Cancer Center · Seattle, WA
- Swedish Cancer Institute · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.